" /> Orvacabtagene Autoleucel - CISMeF





Preferred Label : Orvacabtagene Autoleucel;

NCIt synonyms : Autologous BCMA 41BBz CAR-T Cell JCARH-125; Autologous Anti-BCMA CAR-T Cells JCARH 125; Autologous BCMA-specific CAR4-1BB-CD3zeta-expressing CD4 /CD8 T Lymphocytes JCARH 125; Autologous BCMA-specific CAR-T Cells JCARH125; Autologous Anti-BCMA-CAR-4-1BB-CD3zeta-expressing CD4 /CD8 T-lymphocytes JCARH125;

NCIt definition : A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been ex vivo transduced with a genetically-engineered lentiviral vector (LV) expressing a chimeric antigen receptor (CAR) containing a single chain variable fragment (scFv) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) fused to the co-stimulatory domain of 4-1BB (CD137) and the CD3-zeta (CD3z) T-cell signaling domain, with potential immunostimulating and antineoplastic activities. Upon administration, orvacabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.;

UNII : K8RW1TW3EM;

Molecule name : JCARH 125; JCARH-125;

NCI Metathesaurus CUI : CL545333;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
15/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.